Showing results (81-90 of 175) with videos related to
Sort By:
Pageof 18
Clinical Lung Cancer|July 3, 2020
Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834)Satoru Miura, Takeharu Yamanaka, Terufumi Kato, et al.Respiratory Medicine Case Reports|September 17, 2024
Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapyMasahiro Yamashita, Hisao Higo, Nobuharu Fujii, et al.Cancer Chemotherapy and Pharmacology|October 3, 2018
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403Naohiro Oda, Kastuyuki Hotta, Kiichiro Ninomiya, et al.Internal Medicine (Tokyo, Japan)|August 10, 2021
Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western JapanEri Ando, Takamasa Nakasuka, Toshio Kubo, et al.Oncology Letters|August 13, 2021
Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expressionKazuya Nishii, Kadoaki Ohashi, Hiromi Watanabe, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 10, 2018
A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung CancerKatsuyuki Hotta, Keisuke Aoe, Toshiyuki Kozuki, et al.Internal Medicine (Tokyo, Japan)|March 29, 2021
Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related DiseaseSachi Okawa, Kammei Rai, Nobuharu Fujii, et al.Respiratory Investigation|July 22, 2023
Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancerToshio Kubo, Eiki Ichihara, Daijiro Harada, et al.Lung Cancer (Amsterdam, Netherlands)|July 6, 2026
ULK1, a novel therapeutic target to delay drug tolerance to EGFR-TKIs in an EGFR-mutant non-small cell lung cancer modelAyako Morita, Kammei Rai, Tadahiro Kuribayashi, et al.Japanese Journal of Clinical Oncology|February 23, 2019
Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalitiesHisao Higo, Toshio Kubo, Satoko Makimoto, et al.Pageof 18